• Access Pharmaceuticals Inc., of Dallas, said top-line results from a Phase IV study showed that Mugard mucoadhesive oral wound rinse met the primary study endpoint, with patients receiving the product experiencing a statistically significant reduction vs. placebo in mouth and throat soreness.